Behavioral and psychological symptoms of dementia (BPSD) in elderly demented subjects: Is the long lasting use of atypical antipsychotic drugs useful and safe?

Archives of Gerontology and Geriatrics

Volumn 44, Issue SUPPL., 2007, Pages 35-43

  Angelini, A ^a   Bendini, C ^a   Neviani, F ^a   Neri, M ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Atypical antipsy chotic drugs; Behavioral and psychological symptoms of dementia (BPSD); Drug efficacy in elderly; Drug safety in long lasting use

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ACADEMIC ACHIEVEMENT; AGED; AGGRESSION; AGITATION; ALZHEIMER DISEASE; ARTICLE; BEHAVIOR DISORDER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHRONIC DRUG ADMINISTRATION; CLINICAL ARTICLE; COGNITIVE DEFECT; DAILY LIFE ACTIVITY; DELUSION; DEMENTIA; DISEASE SEVERITY; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FRONTOTEMPORAL DEMENTIA; FUNCTIONAL ASSESSMENT; GERONTOPSYCHIATRY; GYNECOMASTIA; HALLUCINATION; HUMAN; INSTITUTIONALIZATION; INTERNATIONAL CLASSIFICATION OF DISEASES; LONGITUDINAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MULTIINFARCT DEMENTIA; NEUROPSYCHIATRY; NEUROPSYCHOLOGY; PATIENT SELECTION; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM; TREATMENT DURATION; VERBAL HOSTILITY;

ACTIVITIES OF DAILY LIVING; AGED; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DEMENTIA; FEMALE; FOLLOW-UP STUDIES; HUMANS; INSTITUTIONALIZATION; MALE; PSYCHOMOTOR AGITATION; RETROSPECTIVE STUDIES; RISPERIDONE; SEVERITY OF ILLNESS INDEX;

EPITONIUM;

EID: 33847205731     PISSN: 01674943     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.archger.2007.01.005     Document Type: Article

References (46)

1. Aguero-Torres H., Fratiglioni L., Guo Z., Viitanen M., Von Strauss E., and Winblad B. Dementia is the major cause of functional dependence in the elderly: 3-year follow-up data from a population-based study. Am. J. Public Health 88 (1988) 1452-1456
2. Aupperle P. Management of aggression, agitation, and psychosis in dementia: focus on atypical antipsychotics. Am. J. Alzheimers Dis. Other Demen. 21 (2006) 101-108
3. Ballard C., O'Brien J., Swann A., and James I. Treating Behavioural and Psychological Symptoms of Dementia (2002), Oxoford University Press, Oxford, U.K
4. Brodaty H., Ames D., Snowdon J., Woodward M., Kirwan J., Clarnette R., Lee E., Lyons B., and Grossman F. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. Clin. Psychiatry 64 (2003) 134-143
5. Buse J.B. Metabolic side effects of antipsychotics: focus on hyperglycemia and diabetes. J. Clin. Psychiatry 63 (2002) 37-41
6. Carson S., McDonagh M.S., and Peterson K. A systematic review of the efficacy and safety of atypical antipsychotics in patients with psychological and behavioral symptoms of dementia. J. Am. Geriatr. Soc. 54 (2006) 354-361
7. Chui H.C., Lyness S.A., Sobel E., and Schneider L.S. Extrapyramidal signs and psychiatric symptoms predict faster cognitive decline in Alzheimer's disease. Arch. Neurol. 51 (1994) 676-681
8. Coen R.F., Swanwick G.R., O'Boyle C.A., and Coakley D. Behaviour disurbance or other predictors of ceren burden in Alzheimer's disease. Int. J. Geriatr. Psychiatry. 12 (1997) 331-336
9. Cohen C.A., Gold D.P., Shulman K.I., Wortley J.T., McDonald G., and Wargon M. Factors determining the decision to institutionalize individuals: a prospective study. Gerontologist 33 (1993) 714-720
10. Cummings J.L. The Neuropsychiatric Inventory: assessing psychopathology in dementia. Neurology 48 Suppl. 6 (1997) S10-S16
11. Cummings J., and Back C. The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer's disease. Am. J. Geriatr. Psychiatry 6 Suppl. 1 (1998) S64-S78
12. De Deyn P.P., Rabheru K., Rasmussen A., Bocksberger J.P., Dautzenberg P.L., Eriksson S., and Lawlor B.A. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 53 (1999) 946-955
13. De Deyn P.P., Carrasco M.M., Deberdt W., Jeandel C., Hay D.P., Feldman P.D., Young C.A., Lehman D.L., and Breier A. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. Int. J. Geriatr. Psychiatry 19 (2004) 115-126
14. Finkel S.I., Costa e Silva J., Cohen G., Miller S., and Sartorius N. Behavioral and psychological signs and symptoms of dementia: a consensus statement of current knowledge and implications for research and treatemnt. Int. Psychogeriatr. 8 Suppl. 3 (1996) 497-500
15. Folstein M.F., Folstein S.E., and McHugh P.R. Mini-Mental State: A practical method for grading the state of patients for the clinician. J. Psychiatr. Res. 12 (1975) 189-198
16. FDA (Food and Drug Administration). (2003): Safety alert - Risperdal. www.fda.gov/medwatch/SAFETY/2003/risperdal.htm.
17. Gonzales-Salvador M.T., Arango C., Lyketsos C.G., and Barba A.C. The stress and psychological morbidity of the Alzheimer patient caregiver. Int. J. Geriatr. Psychiatry 14 (1999) 701-710
18. Gonzales-Salvador T., Lyketsos C.G., Baker A.S., Hovanec L., Roques C., Brandt J., and Steele C. Quality of life in dementia patients in long-term care. Int. J. Geriatr. Psychiatry 15 (2000) 181-189
19. Health Canada (2002): Important drug safety information, October 11, 2002: Risperdal (risperidone) and Cerebrovascular Adverse Events in Placebo-controlled Trials. Retrieved June 28, 2005, from: http://www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt/risperdal/1-e.html.
20. Health Canada (2004): Important drug safety information, March 11, 2004: Zyprexa (olanzapine) and Cerebrovascular Adverse Events in Placebo-controlled Trials. Retrieved June 28, 2005, from: http://www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt/zyprexahpce.html.
21. Herrmann N., and Black S.E. Behavioral disturbances in dementia. Will the real treatment please stand up?. Neurology 55 (2000) 1247-1248
22. Ikeda M., Fukuhara R., Shigenobu K., Hokoishi K., Maki N., Nebu A., Komori K., and Tanabe H. Dementia associated mental, and behavioural disturbances in elderly people in the community: findings from the first Nakayama study. J. Neurol. Neurosurg. Pychiatry 75 (2004) 146-148
23. Jeste D.V., and Finkel S.I. Psychosis and Alzheimer disease and related dementias. Diagnosis criteria for a distinct syndrome. Am. J. Geriatr. Psychiatry 8 (2000) 29-34
24. Jeste D.V., Lacro J.P., Bailey A., Rockwell E., Harris M.J., and Caligiuri M.P. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J. Am. Ger. Soc. 47 (1999) 716-719
25. Jeste D.V., Lacro J.P., Palmer B., Rockwell E., Harris M.J., and Caligiuri M.P. Incidence of tardive dyskinesia in early stages of low-dose treatment with typical neuroleptics in older patients. Am. J. Psychiatry 156 (1999) 309-311
26. Jeste D., Rockwell E., Harris M.J., Lohr J.B., and Lacro J.P. Conventional vs. newer antipsychotics in elderly patients. Am. J. Ger. Psychiatry 7 (1999) 70-76
27. Jost B.C., and Grossberg G.T. The evolution of psychiatric symptoms in Alzheimer's disease: a natural history study. J. Am. Geriatr. Soc. 44 (1996) 1078-1081
28. Kallin K., Jensen J., Olsson L.L., Nyberg L., and Gustafson Y. Why the elderly fall in residential care facilities, and suggested remedies. J. Fam. Practice 53 (2004) 41-52
29. Katz I.R., Jeste D.V., Mintzer J.E., Clyde C., Napolitano J., and Brecher M. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J. Clin. Psychiatry 60 (1999) 107-115
30. Katz S., Ford A.B., Moskowitz R.W., Jackson B.A., and Jaffe M.W. Studies of illness in the aged. The index of ADL; a standardized measure of biological and psychological function. J. Am. Med. Assoc. 18 (1963) 914-921
31. Kaufer D.I., Cummings J.L., Christine D., Bray T., Castellon S., Masterman D., MacMillan A., Ketchel P., and DeKosky S.T. Assessing the impact of neuropsychiatric symptoms in Alzheimer's disease: the Neuropsychiatric Inventory Caregiver Distress Scale. J. Am. Geriatr. Soc. 46 (1998) 210-215
32. Lawlor B.A. Behavioral and psychological symptoms in dementia: the role of atypical antipsychotics. J. Clin. Psychiatry 65 Suppl. 11 (2004) 5-10
33. Lawton M.P., and Brody E.M. Assessment of older people: Self-maintening and instrumental activities of daily living. The Gerontologist 9 (1969) 179-186
34. Liperoti R., Gambassi G., Lapane K.L., Chiang C., Pedone C., Mor V., and Bernabei R. Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics. J. Clin. Psychiatry 66 (2005) 1090-1096
35. Lyketsos C.G., Steinberg M., Tschanz J.T., Norton M.C., Steffens D.C., and Breitner J.C. Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am. J. Psychiatry 157 (2000) 708-714
36. Lysketos C.G., Lopez O., Jones B., Fitzpatrick A.L., Breitner J., and DeKosky S.T. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. J. Am. Med. Assoc. 288 (2002) 1475-1483
37. McShane R., Keene J., Gedling K., Fairburn C., Jacoby R., and Hope T. Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow-up. Br. Med. J. 314 (1997) 266-270
38. Mega M.S., Cummings J.L., Fiorello T., and Gornbein J. The spectrum of behavioral changes in Alzheimer's disease. Neurology 46 (1996) 130-135
39. Melkersson K., and Dahl M.L. Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs 64 (2004) 701-723
40. Neri M., Cortelloni C., Giorgi G., Spanò A., Cipolli C., and Lalla M. La scala SVEBA per la misurazione dello stato emotivo affettivo nell'anziano. Boll. Psicol. Appl. 193-194 (1990) 51-61 in Italian
41. O'Donnell B.F., Drachman D.A., Barnes H.J., Peterson K.E., Swearer J.M., and Lew R.A. Incontinence and troublesome behaviors predict institutionalization in dementia. J. Geriatr. Psychiatry Neurol. 5 (1992) 45-52
42. Olin J.T., Schneider L.S., Katz I.R., Meyers B.S., Alexopoulos G.S., Breitner J.C., Bruce M.L., Caine E.D., Cummings J.L., Devanand D.P., Krishnan K.R., Lyketsos C.G., Lyness J.M., Rabins P.V., Reynolds III C.F., Rovner B.W., Steffens D.C., Tariot P.N., and Lebowitz B.D. Provisional diagnostic criteria for depression of Alzheimer disease. Am. J. Geritr. Psychiatry 10 (2002) 125-128
43. Pearson J.L., Teri L., Reifler B.V., and Raskind M.A. Functional status and cognitive impairment in Alzheimer's patients with and without depression. J. Am. Geriatr. Soc. 37 (1989) 1117-1121
44. Saxe T. Risperidone questioned as dementia first-line treatment. Geriatrics 59 (2004) 11-12
45. Street J.S., Clark W.S., Gannon K.S., Cummings J.L., Bymaster F.P., Tamura R.N., Mitan S.J., Kadam D.L., Sanger T.M., Feldman P.D., Tollefson G.D., and Breier A. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch. Gen. Psychiatry 57 (2000) 968-976
46. Van Iersel M.B., Zuidema S.U., Koopmans R.T., Verhey F.R., and Olde Rikkert M.G. Antipsychotics for behavioural and psychological problems in elderly people with dementia: a systematic review of adverse events. Drugs Aging 22 (2005) 845-858